Sen-Jam Pharma

This is it. Tomorrow, April 3rd at midnight, our community round closes — and the door shuts. You’ve watched us build: 60+ patents World-class manufacturing Clinical trials completed A platform that doesn’t chase one disease — it goes after the root of nearly all of them. You’ve seen Oppenheimer name us a top emerging biotech in longevity. You’ve seen us partner with KVK Tech, Duke, and NIDA. You’ve heard why this isn’t about a single drug — it’s about the engine. And now, that engine is heading into an FDA meeting in June that could change everything. Some of you invested early. Some have been watching. Some just found us. Wherever you are — this is your moment. Because after tonight: The terms change. The valuation changes. The opportunity changes. Be on this side of the story. Invest before midnight → wefunder.com/senjam With gratitude and fire, The Sen-Jam Team

Sen-Jam is gaining real traction. Last week, CEO Jim Iversen joined KingsCrowd to share insights on the raise, the platform’s potential, and the momentum driving the company forward. With over $2.4M already raised and the round closing at the end of this week, this is the moment to lean in—not look back wishing you had. If you’re following what’s next in biotech and inflammation science, this is one to catch. 🎧 Listen on your commute or while making dinner tonight: kingscrowd.com/inside-startup…

Healthcare isn’t broken. It’s just… a teenager. In Episode Two of Unscripted Rx, Jackie Iversen sits down with @JamieHeywood (Alden Scientific) to talk about why medicine needs a systems upgrade — and a dose of humility. “Turning data into knowledge is the new frontier.” They unpack: • Why studying people over time changes everything • How business incentives distort outcomes • Why inflammation sits at the center of complexity • And why the real revolution is prevention This clip says a lot in under a minute. Full episode now live on Spotify + YouTube: bit.ly/3MiDl3m Listen. Share. Rethink what health could be.

Medicine doesn’t have a shortage of drugs. It has a shortage of systems thinking. 🎙️ Unscripted Rx launches with a deep dive on inflammation as root biology—with Jackie Iversen + Duke’s Dr. Alex Limkakeng. ▶️ bit.ly/3NScRpv

Most medicine still treats symptoms. The future treats systems. Here’s why that shift matters more than ever 👇 bit.ly/45z8tlj #inflammation #goodkarmapharma #JPM2026 #senjampharma

⏰ Tomorrow at 11AM EST Join us for Sen-Jam’s Year-End / Year Ahead Executive Webinar — a candid conversation with our founders and leadership team as we close out 2025 and look toward 2026. Big momentum. Real talk. Ask Us Anything. 🔗 Register / join here: bit.ly/3KoB0mu #biotech #clinicaltrials #innovation #leadership #SenJamPharma #goodkarmapharma

We’re closing out 2025 with major momentum — and gearing up for an even bigger 2026. 🚀 TASK Clinical is funding 2/3 of our Phase 3 trial, we’ve welcomed global pharma leader Rute Fernandes to our executive team Jim Iversen Neal Zahn Christine Leonard Jacqueline Iversen, and the horizon has never looked brighter. Join us for Breakthroughs + Horizons: Year End – Year Head, a live executive webinar on Dec 18 at 11AM EST. We’ll share key updates, what’s ahead, and open the floor for your questions. 👉 Register through our link here bit.ly/3KoB0mu — we’d love to have you with us. #biotech #innovation #clinicaltrials #leadership #SenJamPharma

🚀 Big news from Sen-Jam! We’re thrilled to welcome global life sciences leader Rute Fernandes as Executive Advisor. Her 25+ years at Novartis, Shire & Takeda will help accelerate our commercialization strategy and propel our innovative anti-inflammatory pipeline forward. bit.ly/4oHCFBC

Most revolutions don’t start with a bang. They start with a realization: The way we treat disease… isn’t treating us back. A trillion-dollar sickcare system waits for people to break. Then it tries to patch them up. One inflammatory mediator at a time. One specialty drug at a time. One expensive Band-Aid at a time. But here’s the truth: Inflammation isn’t a single switch. It’s a network. Five, six pathways firing in unison. And for decades, pharma has been treating them like isolated strangers. Sen-Jam took a different path. We asked: What if we stopped chasing the smoke… And finally addressed the fire? What if we could modulate the system upstream— Not suppress immunity, but partner with it? Not wait for damage, but prevent it? Not extend sick days… but healthspan? That’s the power of combination immuno-regulators. Simple ingredients. Elegant interactions. A paradigm shift hiding in plain sight. Most people will miss it. Just like most people miss the exact moment their life could change forever. But some won’t. This holiday season, you can invest in the future of healthcare— A future that moves us before we fall, Not after we break. Sen-Jam isn’t just building drugs. We’re building a new operating system for health. And the next decade will belong to companies willing to rethink the old rules. If you believe sickcare is ripe for disruption— If you believe preventative, upstream modulation is where healthspan truly begins— Consider joining us. Invest in the shift. Invest in the future. Invest in what healthcare should have been all along. bit.ly/44b0gne

Jackie Iversen’s TEDx talk just dropped — and it’s a game-changer. She reveals why the hangover may be one of the most powerful biological models for aging & inflammation. Watch it. Like it. Share it. Let’s make this message impossible to ignore. youtube.com/watch?v=S1r6VG…

YOU'RE INVITED 🚨 Webinar Next Thursday 🚨 We’re on The Front Lines of the Inflammation Revolution — and just one week from completing our Phase 2 clinical trial. Join Sen-Jam’s executive team for an inside look at our momentum, partnerships, and the future of inflammation innovation. 💥 Live Q&A | 60 minutes | Limited seats 🔗 [Register now ➜ bit.ly/4oEXXAJ #Biotech #Innovation #Inflammation #ClinicalTrials #SenJampharma #goodkarmapharma

For decades, medicine has missed the forest for the trees. Treating diseases one by one. After symptoms appear. Always too late. At Sen-Jam, we're catching systemic inflammation early—before disease takes insidious root. 1,300+ investors are already in. The longevity revolution is here. Don't miss out on generational wealth and massive social impact ~ Good karma pharma at its best Explore the Opportunity here! bit.ly/44b0gne

The world is ready to talk about systemic inflammation — because when we heal what connects us, every life can flourish.” A message from the #TEDx stage, and a mission for our time. 💫 #SenJampharma #Inflammation #Longevity

We’re honored to be featured in StartUp Health — this article takes you inside how Jackie and Jim Iversen are building a broad-spectrum anti-inflammatory platform to empower longer, healthier lives (read it here) 👇 🔗 bit.ly/3VGDkar In it, you’ll read how we’re positioning Sen-Jam to go beyond symptomatic treatment and address inflammation as the root driver of age-related disease — bringing real value through deep science, clinical rigor, and a mission that scales globally. We’re grateful to already have 1,250+ retail investors who believe in this vision — and we’re still welcoming new partners. If you’ve ever considered joining a mission-driven biotech journey, now is a prime moment. 💡 Explore our campaign. bit.ly/44b0gne 🤝 Join us. Together, we can reshape how healthspan is defined — for everyone, everywhere. — The Sen-Jam Team #senjampharma #goodkarmapharma #startuphealth #longevity #inflammation #crowdfunding

Excited to share that our CEO/Co-Founder, Jim Iversen be speaking at Investment Crowdfunding Week 2025 (Sept 29–Oct 2), hosted by Kingscrowd! Jim will be showcasing how Sen-Jam Pharmaceutical is Transforming Systemic Inflammation -- the Silent Killer -- Into Longer, Healthier Lives. This 4-day virtual event features 40+ startups, 10+ platforms, and top investors exploring the future of online private markets. 👉 Register for free to join this special session and discover the next wave of healthspan-driving innovation: bit.ly/4ngbZYL #InvestmentCrowdfunding #Kingscrowd #Startups #senjampharma #goodkarmapharma

🚀 Join Us Live This Wednesday at 2pm EST! We’re hosting a Founders Webinar to share an exciting update on Sen-Jam’s lead asset, SJP-001 for Alcohol Hangover Prevention – now in Phase 2 clinical trials in Canada. We’ll also highlight its broader relevance to Metabolic Recovery. Some great updates on our advancements and live Q&A on any topic! 👉 Reserve your spot here: bit.ly/3IxJqa4 💡 Plus, don’t miss a special preview: Jackie Iversen, our Co-Founder & Chief Clinical Officer, will give a high-level peek into her upcoming TEDx Boston Longevity Conference talk, where she explores hangovers as a fast-forward model of aging and the future of inflammation science. We look forward to connecting with you! #tedx #Longevity #ClinicalTrials #Innovation #HealthTech #goodkarmapharma #senjampharma

🚀 Longevity: The Next Big Market Disruption Our Co-Founder & Chief Clinical Officer, Jackie Iversen, RPh MS, highlights the Oppenheimer Report on Longevity, which predicts this market will grow 3x larger than the obesity market—and faster. This is the future Wall Street is preparing for, and you have the chance to get in early, before they do. We're also proud to share that Jackie has been invited to speak at the TEDx Boston event, "Unlocking Longevity," where she will shed light on why this space is the ultimate investment frontier. 📌 Read more about Jay Olson’s Oppenheimer podcast & report: wefunder.com/feed/184110-th… 💡 Invest in Sen-Jam today: bit.ly/44b0gne #Longevity #InvestmentOpportunity #Innovation #SenJam #Wefunder #HealthcareRevolution

The Longevity market is exploding—and Sen-Jam is right in the middle of it. Join our leadership team tomorrow for an exclusive investor update where we’ll unpack: 1. Key insights from Oppenheimer’s Longevity Report featuring Sen-Jam 2. Critical progress in our Phase 2 clinical program for SJP-001 3. What’s ahead for licensing, market tailwinds, and why this is the moment for early investors 🔗 Register now to save your spot: bit.ly/45quint Join us and see how Sen-Jam is poised to lead the next wave in healthspan medicine. #goodkarmapharma #senjampharma #longevity

“Longevity is a bigger market opportunity than obesity.” – Jay Olson, Oppenheimer The same way GLP-1s exploded the obesity market into a Wall Street darling, longevity is next. Jay Olson nails it: we’re going from theory to therapy right now—and early investors have a rare moment to get in before the street catches on. At 15:50, Jay spotlights Sen-Jam’s platform—a patented, de-risked combo therapy repurposing two proven drugs, squarely positioned in metabolic restoration, a key subsector he calls “king.” 👑 “This is one of the most exciting but least understood investment areas today… the opportunity is NOW.” 🎧 Listen to the full 20-min podcast: oppenheimer.com/news-media/202… Own an Early Piece of the Longevity Play 🔗 Invest now bit.ly/44b0gne #goodkarmapharma #senjampharma #longevity #oppenheimer #crowdfunding

Meet SJP-001 — the world’s first inflammation-defeating hangover treatment. Now in Phase 2 trials. In a market full of powders, patches & placebo promises, we’re bringing real science to the table. This isn’t about masking headaches. It’s about stopping the inflammatory storm that alcohol leaves behind. 🧬 No liver risk 🚫 No opioids ✅ Real recovery Just months ago, the U.S. Surgeon General warned alcohol raises risk for serious diseases — even cancer. We believe inflammation is the silent culprit. SJP-001 targets it at the source. And unlocks what we call the Healthy Hangover. 📈 Massive demand 💊 No approved treatments ⚡️ Category-defining potential This isn’t just a hangover fix. It’s the next wave in pain + inflammation innovation. 🔗 Invest now bit.ly/44b0gne The hangover market doesn’t need more hype. It needs a molecule that works. #SenJam #SJP001 #HealthyHangover #goodkarmapharma